Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.9023 USD | -1.48% | -2.98% | -36.01% |
May. 13 | Transcript : Lucid Diagnostics Inc., Q1 2024 Earnings Call, May 13, 2024 | |
May. 13 | Lucid Diagnostics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
- For the past year, analysts have significantly revised downwards their profit estimates.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-36.01% | 45.63M | - | ||
+75.56% | 12.55B | B- | ||
-23.35% | 7.51B | C+ | ||
+8.51% | 6.74B | C- | ||
+14.95% | 5.48B | D+ | ||
-14.65% | 4.93B | B | ||
+30.59% | 4.71B | - | ||
-24.40% | 3.83B | B- | ||
-22.61% | 2.9B | C | ||
+49.50% | 2.49B | C- |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- LUCD Stock
- Ratings Lucid Diagnostics Inc.